Dr. Sullivan's research focuses on new and rare immunodeficiencies. She has a long-standing interest in one of the most common of the primary immunodeficiencies – chromosome 22q11.2 deletion syndrome. She also investigates common variable immunodeficiency, as well as the genetics and epigenetics of systemic lupus erythematosus.
As a physician-scientist, Dr. Bernt's goal is to further the understanding of the role of transcriptional regulation in pediatric hematopoietic stem cell biology and leukemia, and translate findings into novel therapies.
Since the completion of the Human Genome Project, there has been a natural surge in biomedical research aimed at gene discovery. Using genome-wide association studies (GWAS), bioinformatics, and other approaches, this process has focused largely on determining what genes are implicated in specific diseases.
Utilizing high-throughput genomic technologies, combined with bioinformatic approaches, the Grant Lab is unraveling genomic puzzles related to traits that impact the lifecycle. Lab leader Struan Grant, PhD, was the first to implicate the role of the strongest common variant reported to date for type 2 diabetes, namely at the TCF7L2 locus, and is being specifically functionally followed up as part of the lab’s ongoing efforts.
The Center for Applied Genomics (CAG) develops new and better ways to diagnose and treat children with genetic disorders, including attention-deficit/hyperactivity disorder, asthma, diabetes, inflammatory bowel disease (IBD), obesity, and numerous rare diseases. With a goal of generating new diagnostic tests and therapies, CAG is among the world's largest genetics research programs and the only pediatric center with state-of-the-art high-throughput genomics technology.